The aim of the present study was to evaluate the role of MCTs in CRC, by assessing the immunohistochemical expression of the MCT isoforms 1, 4, CD147 and the glycolytic metabolic marker GLUT1, and correlate their expressions with clinicopathological parameters in a comprehensive CRC series, including primary tumours and both lymph node and hepatic metastasis. This evidence concerns the gene BSG and colorectal carcinoma.